tbuckley/cabot-search huggingface dataset:
Prognostic significance of reduction rate of Ki-67 after neoadjuvant chemotherapy in breast cancer patients with non-pCR.
Authors: Nobuaki Matsubara, Hirofumi Mukai, Yoichi Naito, Ako Hosono, Kuniaki Itoh, Satoshi Fujii, Kimiyasu Yoneyama, Noriaki Wada
Journal: Journal of Clinical Oncology (2013)

1113 Background: A pathological complete response (pCR) after neoadjuvant chemotherapy (NAC) is well established predictive marker for long-term prognosis in patients (pts) with HER2 or triple negative (TN) breast cancer. However, predictive marker has not been established in pts with non-pCR after NAC yet. Reduction of Ki-67 value after NAC has been reported to be associated with a favorable prognosis. However, the association between the reduction rate of Ki-67 and prognosis has not been investigated in detail. This study investigates whether reduction rate of the Ki-67 could indicate a survival advantage in pts with non-pCR. Methods: A total of 450 pts who had received neoadjuvant anthracycline with or without taxane chemotherapy and surgery were analyzed retrospectively. Ki-67, hormone receptor and HER2 status were examined by immunohistochemistry (IHC) in pre-NAC biopsy samples and post-NAC surgical specimens. Pts with non-pCR were subdivided into threesubgroups according to Ki-67 change after NAC: High-reduction (absolute value of Ki-67 was reduced by &gt; 80% compared with that prior to NAC), low-reduction (absolute value of Ki-67 was reduced by from 0% to 80% compared with that prior to NAC), and increase groups (absolute value of Ki-67 was increased compared with that prior to NAC). The relapse-free survival (RFS) rates were compared among subgroups. Results: pCR was observed in 19.5% of pts. In pts with non-pCR, a reduction in Ki-67 was observed in 64% (232/362 pts) and the median reduction rate was 60%. A total of 15% of pts were in the high-reduction, 63% in the low-reduction and 22% in theincrease group. The median follow-up was 64.5 months. The 5-year RFS rates among three groups were significantly different (p&lt;0.0001). Similar positive results were observed in the HER2(p=0.033), TN (p=0.034) and luminal subtype (p=0.001). Pts in the high-reduction group showed comparable RFS to pts with pCR (hazard ratio 1.12 p=0.792). Conclusions: In pts with non-pCR, the reduction rate of Ki-67 after NAC significantly predicted RFS regardless of their tumor subtypes. Pts who are non-pCR but achieve a high reduction of the Ki-67 can be expected to have a favorable prognosis similar to that of pts with pCR.
American Heart Association Congenital Cardiac Defects Committee of the Council on Cardiovascular Disease in the Young; Council on Clinical Cardiology; Council on Cardiovascular and Stroke Nursing; Council on Cardiovascular Surgery and Anesthesia; and Emergency Cardiovascular Care Committee. Cardiopulmonary Resuscitation in Infants and Children with Cardiac Disease: A Scientific Statement from the American Heart Association.
Authors: BS Marino, S Tabbutt, G Maclaren, MF Hazinski, I Adatia, DL Atkins, PA Checchia
Journal: Circulation (2018)
IBD prevalence in Lothian, Scotland, derived by capture–recapture methodology
Authors: Gareth-Rhys Jones, Mathew Lyons, Nikolas Plevris, Philip W Jenkinson, Cathy Bisset, Christopher Burgess, Shahida Din, James Fulforth, Paul Henderson, Gwo-Tzer Ho, Kathryn Kirkwood, Colin Noble, Alan G Shand, David C Wilson, Ian DR Arnott, Charlie W Lees
Journal: Gut (2019)

Objective IBD prevalence is estimated to be rising, but no detailed, recent UK data are available. The last reported prevalence estimate in the UK was 0.40% in 2003. We aimed to establish the current, and project future, prevalence in Lothian, Scotland. Design We conducted an all-age multiparameter search strategy using inpatient IBD international classification of disease (ICD-10) coding (K50/51)(1997–2018), IBD pathology coding (1990–2018), primary and secondary care prescribing data (2009–2018) and a paediatric registry, (1997–2018) to identify ‘possible’ IBD cases up to 31/08/2018. Diagnoses were manually confirmed through electronic health record review as per Lennard-Jones/Porto criteria. Autoregressive integrated moving average (ARIMA) regression was applied to forecast prevalence to 01/08/2028. Results In total, 24 601 possible IBD cases were identified of which 10 499 were true positives. The point prevalence for IBD in Lothian on 31/08/2018 was 784/100 000 (UC 432/100 000, Crohn’s disease 284/100 000 and IBD unclassified (IBDU) 68/100 000). Capture–recapture methods identified an additional 427 ‘missed’ cases (95% CI 383 to 477) resulting in a ‘true’ prevalence of 832/100 000 (95% CI 827 to 837). Prevalence increased by 4.3% per year between 2008 and 2018 (95% CI +3.7 to +4.9%, p&lt;0.0001). ARIMA modelling projected a point prevalence on 01/08/2028 of 1.02% (95% CI 0.97% to 1.07%) that will affect an estimated 1.53% (95% CI 1.37% to 1.69%) of those &gt;80 years of age. Conclusions We report a rigorously validated IBD cohort with all-age point prevalence on 31/08/2018 of 1 in 125, one of the highest worldwide.
Free Iron in Sera of Patients with Sickle Cell Disease Contributes to the Release of Neutrophil Extracellular Traps
Authors: Kristof Van Avondt, Marein Schimmel, Ingrid Bulder, Robin van Bruggen, Bart J. Biemond, Brenda M. Luken, Sacha S. Zeerleder
Journal: Blood (2016)
Exact Science and the Art of Approximating Quality in Hospital Performance Metrics
Authors: Mary S. Vaughan Sarrazin, Saket Girotra
Journal: JAMA Network Open (2019)

Harlan M. Krumholz, MD, SM; Andreas C. Coppi, PhD; Frederick Warner, PhD; Elizabeth W. Triche, PhD; Shu-Xia Li, PhD; Shiwani Mahajan, MBBS; Yixin Li, MS; Susannah M. Bernheim, MD, MHS; Jacqueline Grady, MS; Karen Dorsey, MD, PhD; Zhenqiu Lin, PhD; Sharon-Lise T. Normand, PhD
68Ga-DOTATATE Uptake by Cervicothoracic (Stellate) Ganglia
Authors: Zachary Berg, Bhasker Rao Koppula
Journal: Clinical Nuclear Medicine (2019)

Abstract 68 Ga-DOTATATE PET/CT, a functional imaging modality for assessment of well-differentiated neuroendocrine tumors, targeting the somatostatin receptors, has essentially replaced the conventional gamma camera-based imaging with 111 In-labeled octreotide. Physiologic distribution, normal variations, and common pitfalls with 68 Ga-DOTATATE imaging have been well described in the literature. Here, we describe uptake of 68 Ga-DOTATATE in 2 different patients at cervicothoracic junction within the stellate ganglia.
A Single-Cell Transcriptomic Atlas of Human Neocortical Development during Mid-gestation
Authors: Damon Polioudakis, Luis de la Torre-Ubieta, Justin Langerman, Andrew G. Elkins, Xu Shi, Jason L. Stein, Celine K. Vuong, Susanne Nichterwitz, Melinda Gevorgian, Carli K. Opland, Daning Lu, William Connell, Elizabeth K. Ruzzo, Jennifer K. Lowe, Tarik Hadzic, Flora I. Hinz, Shan Sabri, William E. Lowry, Mark B. Gerstein, Kathrin Plath, Daniel H. Geschwind
Journal: Neuron (2019)
Abstract 14432: Selective Serotonin Reuptake Inhibitors Exert a Negative Effect On Peripheral Wave Reflections
Authors: Vasiliki Katsi, Ioannis Skiadas, Konstantinos Kontoangelos, Georgios Souretis, Dimitrios Tsartsalis, Evangelos Vergopoulos, Georgios N Papadimitriou, Christodoulos Stefanadis, Ioannis Kallikazaros
Journal: Circulation (2010)

Introduction: In view of the high likelihood that hypertensives will have comorbid anxiety and depression, all hypertensives should be screened for concurrent psychiatric illnesses and treatment. H...
Prevalence of Inappropriateness of Parenteral Vitamin B<sub>12</sub> Administration in Ontario, Canada
Authors: William K. Silverstein, Yulia Lin, Christoffer Dharma, Ruth Croxford, Craig C. Earle, Matthew C. Cheung
Journal: JAMA Internal Medicine (2019)

Results | A total of 60 consecutive patients (32 men [67%]; mean [SD] age, 62.1 [13.1] years) were enrolled in the study, and after exclusion of those who withdrew consent (n = 4), did not attend DOT (n = 4), or missed subsequent ABPM (n = 4), 48 participants completed this study for the primary outcome and 46 for the secondary outcome.Baseline characteristics are reported in Table 1.After DOT, daytime systolic BP remained 135 mm Hg or greater in 34 of 48 patients (71%) who experienced a mean (SD) decrease in systolic BP of 3 (10) mm Hg.In contrast, in 14 participants (29%), treatment-resistant hypertension resolved and systolic BP decreased by 26 (20) mm Hg (Table 2).This proportion was similar at 1 month in 14 of 46 patients (30%) who no longer had treatment-resistant hypertension.Discussion | The results suggest that nonadherence to BPlowering drug regimens is high among referred patients with apparent treatment-resistant hypertension, even among those who said they were adherent on questioning before DOT, had pristine pharmacy filling records, and had accurate pill counts.Moreover, this apparent nonadherence occurred despite more than 50% of these patients already having had an adverse vascular event related to uncontrolled hypertension.However, we cannot exclude the possibility that the process of being in the study or receiving treatment from a nurse in a clinic was associated with lower BP for some patients.Of interest, most of those with markedly improved BP after DOT had a sustained improvement in BP control seen at 1 month.Limitations of the study include that the patients were highly selected and likely do not represent most patients with hypertension in the community.The use of DOT as described here was strictly dichotomous (adherence vs nonadherence) and thus does not allow for precise assessment of the degree of nonadherence (eg, partial vs complete), as may be the case with therapeutic drug monitoring. 5,6 Overall, the findings suggest that rigorous methods of adherence assessment and intervention such as DOT should be considered for patients with apparent treatmentresistant hypertension.
Bowel preparation for colonoscopy: European Society of Gastrointestinal Endoscopy (ESGE) Guideline – Update 2019
Authors: Cesare Hassan, James East, Franco Radaelli, Cristiano Spada, Robert Benamouzig, Raf Bisschops, Michael Bretthauer, E. Dekker, Mario Dinis-Ribeiro, Monika Ferlitsch, Lorenzo Fuccio, Halim Awadie, Ian Gralnek, Rodrigo Jover, Michal F. Kaminski, Maria Pellisé, Konstantinos Triantafyllou, Giuseppe Vanella, Carolina Mangas-Sanjuan, Leonardo Frazzoni, Jeanin E. Van Hooft, Jean-Marc Dumonceau
Journal: Endoscopy (2019)

ESGE recommends a low fiber diet on the day preceding colonoscopy.Strong recommendation, moderate quality evidence.ESGE recommends the use of enhanced instructions for bowel preparation.Strong recommendation, moderate quality evidence.ESGE suggests adding oral simethicone to bowel preparation.Weak recommendation, moderate quality evidence.ESGE recommends split-dose bowel preparation for elective colonoscopy.Strong recommendation, high quality evidence.ESGE recommends, for patients undergoing afternoon colonoscopy, a same-day bowel preparation as an acceptable alternative to split dosing.Strong recommendation, high quality evidence.ESGE recommends to start the last dose of bowel preparation within 5 hours of colonoscopy, and to complete it at least 2 hours before the beginning of the procedure.Strong recommendation, moderate quality evidence.ESGE recommends the use of high volume or low volume PEG-based regimens as well as that of non-PEG-based agents that have been clinically validated for routine bowel preparation. In patients at risk for hydroelectrolyte disturbances, the choice of laxative should be individualized.Strong recommendation, moderate quality evidence.
Why Do You Want to Be a Physician?
Authors: Adam S. Cifu
Journal: JAMA Neurology (2019)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Neurology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Neurology journal
ELARA: A phase II, single-arm, multicenter, open-label trial investigating the efficacy and safety of tisagenlecleucel in adult patients with refractory/relapsed follicular lymphoma (r/r FL).
Authors: Michael Dickinson, Leslie Popplewell, Arne Kolstad, Joy Ho, Takanori Teshima, Martin H. Dreyling, Stephen J. Schuster, Catherine Thieblemont, Nigel Yateman, Katja Lehnhoff, Tomasz Lawniczek, Lida Bubuteishvili-Pacaud, Nathan Hale Fowler
Journal: Journal of Clinical Oncology (2019)

TPS7573 Background: Tisagenlecleucel is an anti-CD19 chimeric antigen receptor-T cell (CAR-T) therapy that was approved for the treatment of pediatric and young adult patients up to 25 years of age with r/r B-cell acute lymphoblastic leukemia in 2017 (Maude et al. NEJM. 2018), as well as for the treatment of adult patients with r/r diffuse large B-cell lymphoma in 2018 (Schuster et al. NEJM. 2018). FL is the second most common non-Hodgkin lymphoma in the Western hemisphere, with limited treatment options in patients refractory to or relapsing after standard therapies. In a phase 2a study of patients with r/r CD19+ lymphomas, 10 of 14 (71%) patients with r/r FL treated with tisagenlecleucel achieved a durable complete remission at a median follow-up of 28.6 months (Schuster et al. NEJM. 2017). Here we introduce ELARA, a phase 2 study evaluating the efficacy and safety of tisagenlecleucel in patients with r/r FL. Methods: ELARA is a phase 2, single-arm, multicenter, open label trial. Eligible patients must be ≥18 years of age, have radiographically measurable grade 1, 2, or 3A r/r FL that is refractory to a second or later line of systemic therapy (including an anti-CD20 antibody and an alkylator), or relapsed within 6 months after completion of a second or later line of systemic therapy, or relapsed during anti-CD20 antibody maintenance (following ≥2 lines of therapy as above) or within 6 months after maintenance completion, or relapsed after autologous hematopoietic stem cell transplant (HSCT). Patients with central nervous system involvement, or those who received prior anti-CD19 therapy, gene therapy, adoptive T-cell therapy, or allogeneic HSCT are not eligible. The primary endpoint of this study is complete response rate based on Lugano classification response criteria. Secondary outcomes include overall response rate, duration of response, overall survival, cellular kinetics, immunogenicity, safety, and patient-reported outcomes. Estimated enrollment for this study is 113 patients. The study is currently open to patient enrollment. Clinical trial information: NCT03568461.
Celiac Disease on FDG PET/CT
Authors: Anthony Joshua Cardin, Mihir Patel, Dickson Ma
Journal: Clinical Nuclear Medicine (2019)

Abstract An FDG PET with diagnostic CT was performed on a 52-year-old man for investigation of lymphocytosis and the clinical suspicion of lymphoma. The PET/CT demonstrated diffuse small bowel uptake, prominent mesenteric lymph nodes without significant FDG uptake, and other features suggestive of celiac disease. Subsequently, the patient was found to have markedly elevated celiac disease antibodies (deamidated gliadin IgG and tissue transglutaminase IgA) and to be HLA DQ2 and DQ8 allele positive on genotyping for celiac disease. Gastroscopy and duodenal biopsy also confirmed the diagnosed.
Long-Term Outcomes after Acute Rejection in Kidney Transplant Recipients: An ANZDATA Analysis
Authors: Philip A. Clayton, Stephen P. McDonald, Graeme R. Russ, Steven J. Chadban
Journal: Journal of the American Society of Nephrology (2019)

Significance Statement Declining rates of acute rejection (AR) and the very high rate of 1-year graft survival among patients with AR has led some clinicians and researchers to reconsider the importance of AR as a primary outcome in clinical trials or in patients. The authors examine the association of AR within 6 months of kidney transplant with long-term outcomes of transplant recipients, using data from the Australia and New Zealand Dialysis and Transplant (ANZDATA) Registry between 1997 and 2017. Recipients with early AR were more likely to experience graft loss attributed to chronic allograft nephropathy (hazard ratio [HR], 1.39; 95% confidence interval [95% CI], 1.23 to 1.56) and recurrent AR (HR, 1.85; 95% CI, 1.39 to 2.46). Recipients with early AR were also more likely to die from cardiovascular disease (HR, 1.30; 95% CI, 1.11 to 1.53) or cancer (HR, 1.35; 95% CI, 1.12 to 1.64). AR therefore remains an important short-term outcome in kidney transplantation with significant long-term effects. Background Declining rates of acute rejection (AR) and the high rate of 1-year graft survival among patients with AR have prompted re-examination of AR as an outcome in the clinic and in trials. Yet AR and its treatment may directly or indirectly affect longer-term outcomes for kidney transplant recipients. Methods To understand the long-term effect of AR on outcomes, we analyzed data from the Australia and New Zealand Dialysis and Transplant Registry, including 13,614 recipients of a primary kidney-only transplant between 1997 and 2017 with at least 6 months of graft function. The associations between AR within 6 months post-transplant and subsequent cause-specific graft loss and death were determined using Cox models adjusted for baseline donor, recipient, and transplant characteristics. Results AR occurred in 2906 recipients (21.4%) and was associated with graft loss attributed to chronic allograft nephropathy (hazard ratio [HR], 1.39; 95% confidence interval [95% CI], 1.23 to 1.56) and recurrent AR beyond month 6 (HR, 1.85; 95% CI, 1.39 to 2.46). Early AR was also associated with death with a functioning graft (HR, 1.22; 95% CI, 1.08 to 1.36), and with death due to cardiovascular disease (HR, 1.30; 95% CI, 1.11 to 1.53) and cancer (HR, 1.35; 95% CI, 1.12 to 1.64). Sensitivity analyses restricted to subgroups with either biopsy-proven, antibody-mediated, or vascular rejection, or stratified by treatment response produced similar results. Conclusions AR is associated with increased risks of longer-term graft failure and death, particularly death from cardiovascular disease and cancer. The results suggest AR remains an important short-term outcome to monitor in kidney transplantation and clinical trials.
Randomized phase II trial of patient-specific dendritic cell vaccines loaded with autologous tumor antigens versus autologous monocytes in patients with primary advanced ovarian cancer.
Authors: Robert O. Dillman, Lisa Abaid, Candace Hsieh, Christopher Langford, Gabriel I. Nistor
Journal: Journal of Clinical Oncology (2019)

TPS10 Background: With standard debulking surgery and combination chemotherapy (adjuvant ± neoadjuvant) the 5-year survival for women with newly diagnosed advanced epithelial ovarian cancer (stage III or IV) is less than 40%. After completion of primary therapy there is an opportunity to introduce an immunotherapy modality in an effort to improve long-term survival. In patients with metastatic melanoma, patient-specific vaccines consisting of autologous dendritic cells (DC) loaded with autologous tumor antigens (ATA) derived from a short-term autologous tumor cell line were associated with minimal toxicity and a 5-year survival of 50% in a single arm trial, and more than doubled median survival (43 vs. 20 months) in a randomized trial. Newly diagnosed patients with ovarian cancer might benefit from addition of such patient-specific therapeutic vaccines (DC-ATA) to standard therapy. Methods: This is a double-blind, 2:1 randomized trial comparing adjunctive treatment with DC-ATA to autologous monocytes (MC) in patients with newly diagnosed stage III or IV epithelial cancer of the ovary, fallopian tube, or peritoneum. Patients eligible for randomization are those who have completed or discontinued standard primary therapy, have a Karnofsky performance status ≥70, have an autologous tumor cell line, and have a monocyte product from which DC can be derived. The tumor cell line is derived from fresh tumor; MC are derived from leukapheresis, and MC are converted to DC by incubation with GM-CSF and IL-4. Patients are stratified by whether there is no evidence of disease at completion of primary therapy, and then are randomized, typically 6 to 7 months after tumor collection. Treatment can begin about 4 weeks from randomization. The trial has been open at a single site since mid-November 2017; the first tumor was collected in December. Appropriate tumor samples have been submitted from 11 patients and all 11 have resulted in cell lines. The first patient was randomized in May 2018. As of October 2018 four patients had been randomized and all four had started treatment. Additional clinical sites are being initiated. Clinical trial information: NCT02033616.
68Ga–Prostate-Specific Membrane Antigen Uptake in a Malignant Pleural Effusion From Metastatic Prostate Cancer After Pleurodesis
Authors: Christos Sachpekidis, Ian Alberts, Axel Rominger, Ali Afshar-Oromieh
Journal: Clinical Nuclear Medicine (2019)

Abstract A 76-year-old man with metastatic adenocarcinoma of the prostate presented with increasing dyspnea. After being treated initially with drainage and afterwards with pleurodesis, he was referred for 68 Ga–prostate-specific membrane antigen 11 PET/CT imaging for restaging purposes. PET/CT demonstrated extensive 68 Ga–prostate-specific membrane antigen 11 uptake in the right pleura. Histopathology confirmed the rare case of malignant pleural effusion from metastatic prostate cancer.